Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Authors: Molife, L.R., Hickish, T. et al.
Journal: Future Oncology
Volume: 10
Issue: 2
Pages: 219-231
eISSN: 1744-8301
ISSN: 1479-6694
DOI: 10.2217/fon.13.250
Abstract:Aims: The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients. Patients & methods: Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks. Results: Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy. Conclusion: Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients. © 2014 Future Medicine Ltd.
Source: Scopus
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Authors: Molife, L.R., Hickish, T. et al.
Journal: Future Oncol
Volume: 10
Issue: 2
Pages: 219-231
eISSN: 1744-8301
DOI: 10.2217/fon.13.250
Abstract:AIMS: The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients. PATIENTS & METHODS: Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks. RESULTS: Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy. CONCLUSION: Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.
Source: PubMed
Preferred by: Tamas Hickish
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Authors: Molife, L.R., Hickish, T. et al.
Journal: FUTURE ONCOLOGY
Volume: 10
Issue: 2
Pages: 219-231
eISSN: 1744-8301
ISSN: 1479-6694
DOI: 10.2217/FON.13.250
Source: Web of Science (Lite)
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Authors: Molife, L.R., Hickish, T. et al.
Journal: Future oncology (London, England)
Volume: 10
Issue: 2
Pages: 219-231
eISSN: 1744-8301
ISSN: 1479-6694
DOI: 10.2217/fon.13.250
Abstract:Aims
The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients.Patients & methods
Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks.Results
Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy.Conclusion
Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.Source: Europe PubMed Central